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Tolerogenic dendritic cells (DCs) are a promising tool to control T cell-mediated autoim-
munity. Here, we evaluate the ability of dexamethasone-modulated and monophosphoryl 
lipid A (MPLA)-activated DCs [MPLA-tolerogenic DCs (tDCs)] to exert immunomodu-
latory effects on naive and memory CD4+ T cells in an antigen-specific manner. For 
this purpose, MPLA-tDCs were loaded with purified protein derivative (PPD) as antigen 
and co-cultured with autologous naive or memory CD4+ T cells. Lymphocytes were 
 re-challenged with autologous PPD-pulsed mature DCs (mDCs), evaluating prolifer-
ation and cytokine production by flow cytometry. On primed-naive CD4+ T cells, the 
expression of regulatory T cell markers was evaluated and their suppressive ability was 
assessed in autologous co-cultures with CD4+ effector T cells and PPD-pulsed mDCs. 
We detected that memory CD4+ T cells primed by MPLA-tDCs presented reduced 
proliferation and proinflammatory cytokine expression in response to PPD and were 
refractory to subsequent stimulation. Naive CD4+ T cells were instructed by MPLA-tDCs 
to be hypor esponsive to antigen-specific restimulation and to suppress the induction of 
T helper cell type 1 and 17 responses. In conclusion, MPLA-tDCs are able to modulate 
antigen-specific responses of both naive and memory CD4+ T cells and might be a 
promising strategy to “turn off” self-reactive CD4+ effector T cells in autoimmunity.
Keywords: tolerance, monocyte-derived dendritic cells, hyporesponsiveness, naive cD4+ T cells, memory cD4+ 
T cells, immunotherapy
inTrODUcTiOn
One of the main challenges in the field of autoimmunity is the attenuation of aberrant T cell immune 
responses to “self.” Current treatments, such as immunosuppressive drugs, evoke undesired side 
effects and an increased probability of acquiring infectious diseases and cancer (1, 2). In this context, 
a novel and promising immunotherapeutic strategy to specifically control T cell-mediated patholo-
gies is the use of ex vivo-modulated dendritic cells (DCs) (3).
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Dendritic cells have been described as the most potent 
antigen-presenting cells and are fundamental for the initiation of 
an effective immune response (4). Depending on their matura-
tion stage, DCs are able to induce or inhibit T cell responses (5): 
while immature and semi-mature DCs are considered tolerogenic 
(tDCs), mature DCs (mDCs) are immunogenic. tDCs exhibit 
a reduced costimulatory capacity and an anti-inflammatory 
cytokine secretion profile and are able to modulate CD4+ T cell 
responses (6, 7). The mechanisms by which tDCs exert their 
modulatory activity on autoreactive T cells include clonal dele-
tion, anergy induction, or cell reprograming. Additionally, tDCs 
are able to promote the differentiation and proliferation of T cells 
with regulatory functions (Treg) (8).
It has been reported that tDCs have great therapeutic potential. 
Injection of ex vivo modified tDCs has provided improvement 
in murine models of autoimmune diseases, including arthritis 
(9–12), diabetes (13, 14), and multiple sclerosis (15). In humans, 
phase I clinical trials using tDCs have been carried out in patients 
with type 1 diabetes (16) and rheumatoid arthritis (17, 18). In 
all cases, treatment was well tolerated by patients without side 
effects, justifying further studies to evaluate their clinical efficacy 
and antigen-specific impact.
There are different methods for in  vitro generation of tDCs 
from peripheral blood monocytes (19), such as genetic modifica-
tion (20–22), pharmacological modulation (e.g., with vitamin 
D3, dexamethasone, or rapamycin) (6, 23, 24), or treatment 
with anti-inflammatory cytokines, IL-10 or TGF-β (25). It has 
been described that alternative activation of tDCs, induced by 
proinflammatory mediators, such as TNF-α, IL-1, and IL-6, or 
toll-like receptor ligands, such as LPS, improves their antigen-
presenting capacity and endows them with the ability to migrate 
to secondary lymphoid organs (26–28).
Recently, we described a 5-day protocol for the generation of 
stable semi-mature monocyte-derived tDCs using dexametha-
sone (Dex), as immunomodulatory agent, and monophosphoryl 
lipid A (MPLA), a non-toxic (GMP-compatible) LPS analog, as 
activating stimulus (MPLA-tDCs). Similar to Dex-modulated 
tDCs, which have been well described as tolerogenic, these 
MPLA-tDCs are characterized by a reduced expression of 
costimulatory molecules (CD80, CD86, and CD40), an IL-10high/
IL-12low cytokine secretion profile, and a reduced ability to 
stimulate proliferation and proinflammatory cytokine secretion 
of allogeneic and antigen-specific CD4+ T cells. Importantly, the 
activation of MPLA-tDCs using MPLA upregulates expression of 
CCR7 and CXCR4 chemokine receptors in comparison to tDCs, 
conferring to MPLA-tDCs the lymph node homing-capacity, 
which together with their potential to induce high levels of IL-10 
secretion in co-cultures with CD4+ T cells suggests that MPLA-
tDCs might be superior to Dex-modulated tDCs regarding loca-
tion for interacting with autoreactive effector CD4+ T cells and 
subsequent tolerance recovery (26).
To validate the suitability of MPLA-tDCs for autologous 
immunotherapy of autoimmune disorders, it is crucial to confirm 
their ability to act at different levels of an immune response, either 
by directing differentiation of naive CD4+ T cells with certain 
antigen-specificity toward a regulatory profile or by reprogram-
ing autoreactive memory CD4+ T cells. Different studies reported 
the effects of Dex-modulated tDCs on CD4+ T cell subsets in 
allogeneic models, with controversial conclusions. It has been 
described that both naive and memory CD4+ T cells primed by 
Dex-modulated tDCs become hyporesponsive upon restimula-
tion with mDCs via the induction of anergy (29). Other studies 
showed that tDCs generated with Dex alone, or in combination 
with vitamin D3 and LPS, polarize naive CD4+ T cells toward 
Treg cells with an IFNγlow/IL-10high cytokine profile, while render-
ing memory CD4+ T cells anergic (27).
In this work, we investigated the modulation of antigen-specific 
naive and memory CD4+ T cell responses by MPLA-tDCs to get 
further insight into their immunomodulatory mechanisms. We 
demonstrate that MPLA-tDCs display a reduced ability to induce 
proliferation and proinflammatory cytokine production of CD4+ 
memory T cells and promote hyporesponsiveness to restimula-
tion. Furthermore, we show that MPLA-tDCs are capable of 
instructing naive CD4+ T cells at the priming, reducing prolifera-
tion and secretion of proinflammatory cytokines in response to 
restimulation and conferring them the ability to suppress T helper 
type 1 (Th1) and Th17 responses. This confirms that MPLA-tDCs 
are able to reprogram antigen-specific naive and memory CD4+ 
T cell responses.
MaTerials anD MeThODs
samples and isolation of cell Populations
Buffy coats from healthy donors were obtained from the Blood 
Bank of Clinical Hospital from Universidad de Chile. All donors 
had been vaccinated with Bacillus Calmette–Guérin (BCG), 
resulting in T cell reactivity against purified protein derivative 
(PPD) antigen. CD14+ monocytes were obtained by negative 
selection using RosetteSep® Human Monocyte Enrichment 
Cocktail (Stem Cell Technologies, Vancouver, BC, Canada), 
followed by density gradient centrifugation with Lymphoprep 
(Axis-Shield Diagnostics, Dundee, UK). CD45RA+/RO− naive 
and CD45RA–/RO+ memory CD4+ T cells were purified from 
PBMC by negative magnetic selection using EasySep™ Human 
Naive or Memory CD4+ T Cell Enrichment Kits (StemCell 
Technologies), respectively.
Subjects signed an informed written consent according to the 
Declaration of Helsinki, and all procedures were approved by the 
Ethics Committees of the Faculty of Medicine and the Clinical 
Hospital of University of Chile.
generation of Dendritic cells
Dendritic cells were generated from monocytes and cultured at 
2–3 × 106 cells/ml in AIM-V serum-free medium (GIBCO BLR, 
Invitrogen, Grand Island, USA), in the presence of rhIL-4 and 
rhGM-CSF (500 U/ml each; eBioscience, San Diego, CA, USA) 
for 5  days at 37°C and 5% CO2 (26). Activated tDCs (MPLA-
tDCs) were generated by addition of 1 μM Dex (Sigma-Aldrich, 
St. Louis, MO, USA) at day 3 and 1 μg/ml MPLA (Avanti Polar 
Lipids Inc., Alabaster, AL, USA) 24 h later. Three controls were 
used: untreated immature cells (iDCs), tolerogenic Dex-treated 
DCs (tDCs), and mature MPLA-treated DCs (mDCs). On day 
5, cells were harvested and phenotypic and functional analyses 
were performed.
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Flow cytometry analysis
The following antibodies were used for flow cytometry analysis: 
CD11c APC, CD80 FITC, CD83 FITC, CD86 PE, HLA-DR 
FITC, CD1a FITC, CD14 FITC, CD4PE, CD4 PE-Cy7, 
CD45RA PE, CD45RO FITC, CD25 PE-Cy7, CTLA-4 APC, 
CD39 PerCP-eFluor710, FOXP3 Alexa Fluor 700, IL-10 PE, 
IFN-γ PE-Cy7, and IL-17 APC (all eBioscience). For surface 
staining, cells were incubated in PBS 10% FBS containing the 
respective antibodies for 30  min at 4°C, washed, and stored 
in IC fixation buffer until analysis (eBioscience). Intracellular 
FoxP3 was detected using FoxP3-staining kit (eBioscience) 
according to the manufacturer’s instructions. For intracellular 
cytokines detection, cells were treated with 50  ng/ml PMA, 
1  μg/ml ionomycin, and 1  μl/ml brefeldin A for 5  h. After 
harvesting, cells were surface stained for CD4. Intracellular 
cytokine staining was performed in permeabilization buffer 
(eBioscience) before cells were washed and resuspended in 
FACS buffer for flow cytometry analysis. Cell viability was 
assessed by 7-AAD and annexin-V PE staining (eBioscience). 
Data were collected on FACSCalibur and FACSAria cytometers 
(Beckton Dickinson, San Diego, CA, USA) and analyzed with 
Weasel v3.0.2 software.
antigen Uptake assay
Dendritic cells were incubated with 1 mg/ml of dextran (DX)-
FITC (40  kDa; Molecular Probes, Leiden, Netherlands) for 1, 
2, and 4 h at 37 or 4°C (negative control). Uptake was stopped 
with cold PBS, and samples were analyzed by flow cytometry. 
Endocytosis capacity is represented by the difference between 
FITC mean fluorescence intensity (MFI) of cells incubated at 
37°C and cells incubated at 4°C.
antigen Presentation assay
Different subtypes of DCs were generated from HLA DRB1*0101 
donors, as described above. On day 4, DCs were loaded with 
human type II collagen peptide hCII259–273 or an irrelevant chicken 
peptide, 6 h before addition of MPLA. Unloaded DCs were used 
as control. On day 5, DCs were fixed with paraformaldehyde and 
co-cultured with the transgenic murine HLA-DR1-restricted 
T cell hybridoma HCII-9.1, specific for the non-glycosylated ver-
sion of the immunodominant T cell epitope of hCII (hCII259–273) 
(30). Co-culture was performed in RPMI medium supplemented 
with 10% FBS at 1:10 ratio (DCs/HCII-9.1) for 24 h. Supernatants 
were recovered and IL-2 secretion by the T cell hybridoma was 
determined based on the proliferative response of the IL-2-
dependent cytotoxic T cell line-2 (CTLL-2). CTLL-2 cells were 
labeled with 5 μM carboxyfluorescein succinimidyl ester (CFSE; 
Sigma-Aldrich), stimulated with co-culture supernatants for 
24  h, and their proliferation was assessed through dilution of 
CFSE fluorescence by flow cytometry.
antigen-specific T cell stimulation and 
restimulation assays
On day 4 of DC generation, 4 h before stimulation with MPLA, 
DCs were loaded with 1  μg/ml PPD (Staten Serum Institute, 
Copenhagen, Denmark), or left unloaded (controls for unspecific 
stimulation), and incubated for further 24 h. DCs were harvested, 
washed, and co-cultured with CFSE-labeled (primary T cell 
stimulation assay) or unlabeled (restimulation assay) autologous 
naive or memory CD4+ T cells at a ratio of 1:10 (DC/naive T cells) 
and 1:5 (DC/memory T cells) in RPMI medium supplemented 
with 10% FBS, for 6 days. CD4+ T cells alone or stimulated with 
plate-bound anti-human CD3 antibody (OKT3; 0.65  μg/well; 
eBioscience) were used as negative and positive controls for T cell 
activation, respectively.
For restimulation assays, naive or memory CD4+ T cells were 
recovered from initial co-cultures, extensively washed, labeled 
with CFSE, and restimulated with PPD-loaded mDCs from 
the same donor, at a DC/T cell ratio of 1:5. Supernatants were 
collected after 5 days of restimulation and assayed for IL-10 by 
ELISA. T cell proliferation, intracellular cytokine expression, and 
regulatory phenotype markers were assessed by flow cytometry.
T cell suppression assay
Naive CD4+ T cells primed with different PPD-loaded DC sub-
types as described above were recovered, washed, and co-cultured 
with autologous CFSE-labeled responder CD4+ T cells and PPD-
loaded mDCs at a primed-naive T cells/responder CD4+ T cells/
mDCs ratio of 1:1:1. After 5 days, proliferation and intracellular 
cytokine expression of responder CD4+ T cells were determined 
by flow cytometry.
statistical analyses
GraphPad Prism version 5.0 (GraphPad Software, San Diego, 
CA, USA) was used for statistical analyses and graph prepara-
tion. Data distribution was analyzed by Kolmogorov–Smirnov 
test. According to the results of the normality test, Friedman test 
(non-parametric data) or one-way ANOVA (normally distrib-
uted data) for repeated measures, followed by Dunns or Tukey 
post-test, respectively, were used for statistical comparisons. For 
grouped analyses, two-way ANOVA and Bonferroni post-tests 
were applied to compare replicate means by row. P values ≤0.05 
were considered significant.
resUlTs
MPla-tDcs are immature Dendritic cells 
That Present antigen efficiently
MPLA-tDCs, generated using a combination of Dex and MPLA, 
were phenotypically and functionally characterized by flow 
cytometry in comparison to untreated iDCs, MPLA-matured 
mDCs, and Dex-modulated tDCs. All DC subtypes comprised 
>95% CD11c+ cells with a CD1ahigh and CD14low phenotype, 
and DC viability, assessed by 7-AAD and annexin-V staining, 
was not affected by treatment with Dex or MPLA (Figure 1A). 
Phenotypic analysis revealed that MPLA-tDCs exhibited low 
expression levels of the costimulatory molecules CD86 and CD80 
and the maturation marker CD83, similar to iDCs and tDCs, but 
significantly reduced in comparison to mDCs. Concerning the 
human leukocyte antigen HLA-DR, MPLA-tDCs did not present 
significant differences in expression levels as compared to mDCs 
(Figure 1B).
FigUre 1 | MPla-tDcs are characterized by low expression of maturation markers, diminished endocytosis ability, and the capability to present 
antigen efficiently. For the induction of a tolerogenic state, DCs were conditioned with dexamethasone (Dex) and were additionally activated with MPLA 
(MPLA-tDCs). Untreated DCs (iDCs), Dex-modulated DCs (tDCs), and MPLA-matured DCs (mDCs) were used as controls. (a) Representative dot plots of cell 
viability measured after 5 days of culture and expressed as the percentage of annexin-V and 7-AAD-negative cells are shown, and DC yield is expressed as a 
percentage of DCs obtained on day 5 related to the initial number of monocytes cultured per condition (mean ± SEM) (n = 10). (B) Surface expression levels of 
CD86, CD80, CD83, and HLA-DR were assessed by flow cytometry. Graphic analyses of MFI measurements are expressed as box-and-whiskers plot from 
minimum to maximum values (n = 6). Statistical differences were calculated using one-way ANOVA for repeated measures followed by Tukey post-test (*P < 0.05; 
**P < 0.01; ***P < 0.001). (c) Endocytosis capacity was assessed by incubating DCs with dextran-FITC during 1, 2, and 4 h. Results are expressed as the 
difference between MFI of cells incubated at 37 and 4°C with the antigen and are represented as the mean ± SEM of four independent experiments. Significant 
differences are expressed in relation to iDCs condition. (D) For evaluating antigen-presentation ability, DCs generated from HLA-DRB1*0101 donors were pulsed 
with the human type II collagen peptide (hCII259–273) and co-cultured with the HLA-DR1-restricted T cell hybridoma (hCII-9.1). Unpulsed DCs and DCs loaded with 
an irrelevant chicken peptide (iPept) were used as controls. Graphs show the proliferative responses of CTLL-2 cells incubated with supernatants obtained from 
those co-cultures and assessed by flow cytometry. Data are represented as the mean ± SEM of three independent experiments. For (c,D), statistical differences 
were calculated using two-way ANOVA followed by Bonferroni post-test (*P < 0.05; **P < 0.01; ***P < 0.001).
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To determine the capacity of MPLA-tDCs to pick up antigen, 
endocytosis of FITC-conjugated dextran particles was deter-
mined by flow cytometry and compared between different DC 
preparations. While iDCs and tDCs displayed a potent endocytic 
ability that increased with time, MPLA treatment (mDCs and 
MPLA-tDCs) markedly reduced uptake of DX-FITC by DCs, 
especially after prolonged incubation (Figure  1C). Based on 
these results, to favor endocytosis in subsequent assays, DCs 
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were pulsed with the antigen for 4  h before being activated 
with MPLA.
To evaluate if MPLA-tDCs are capable of presenting antigen 
peptides to T cells, DC preparations, generated from HLA 
DRB1*0101 donors and pulsed with the collagen peptide 
hCII259–273, or an irrelevant chicken-derived peptide, were 
co-cultured with the HLA-DR-restricted T cell hybridoma 
HCII-9.1. Recognition of the presented hCII259–273 peptide, but 
not for the irrelevant peptide, by hybridoma cells, induced IL-2 
secretion into culture supernatants, which in turn stimulated the 
proliferation of the IL-2-dependent cell line CTLL-2 (Figure 1D). 
Significant differences were observed between percentages of 
CTLL-2  proliferation induced by IL-2 coming from co-cultures 
performed with mDCs and MPLA-tDCs compared to the other 
conditions (Figure  1D). Proliferative responses of CTLL-2 
revealed that activation with MPLA increase the ability of tDCs 
to present the hCII259–273 peptide efficiently.
MPla-tDcs Modulate responses of 
antigen-specific cD4+ Memory T cells
To determine the capacity of MPLA-tDCs to stimulate memory 
T cell responses, DC preparations, either loaded with PPD or 
unloaded, were co-cultured with autologous memory CD4+ 
T cells, and proliferation and cytokine production were assessed. 
A reduced proliferative response and proinflammatory cytokines 
production were evidenced when memory CD4+ T cells were co-
cultured with different unpulsed DC preparations in comparison 
to pulsed conditions (data not shown). PPD-pulsed mDCs were 
potent inducers of memory CD4+ T cell proliferation. In contrast, 
the immunostimulatory capacity of tDCs and MPLA-tDCs was 
even lower than that of iDCs (Figure 2B). To further characterize 
the type of antigen-specific response induced by each DC subset, 
intracellular expression of IFN-γ and IL-17 by memory CD4+ 
T  cells was assessed (Figure  2A). Both PPD-pulsed iDCs and 
mDCs induced IFN-γ expression in a significantly higher per-
centage of proliferating memory CD4+ T cells than PPD-pulsed 
tDCs or MPLA-tDCs (Figure  2C). IL-17-producing proliferat-
ing memory CD4+ T cells increased significantly in response 
to stimulation with PPD-pulsed mDCs in comparison to 
PPD-pulsed tDCs or MPLA-tDCs (Figure 2D). Antigen-pulsed 
tDCs and MPLA-tDCs were even poorer inducers of proinflam-
matory cytokine responses in memory CD4+ T cells than iDCs 
(Figures 2B,C). A combined staining of annexin-V and 7-AAD 
evidenced that the treatment applied to DCs did not affect the 
viability of memory CD4+ T cells in the co-cultures (Figure 2E).
naive cD4+ T cells Primed by MPla-tDcs 
Do not exhibit a regulatory Phenotype
In order to examine the ability of MPLA-tDCs to modulate naive 
CD4+ T cell responses, PPD-pulsed or unpulsed DC preparations 
were co-cultured with autologous naive CD4+ T cells. After 6 days 
of co-culture, no proliferative responses of naive CD4+ T cells 
were observed, irrespective of whether they were primed by PPD-
loaded iDCs, mDCs, tDCs, or MPLA-tDCs (data not shown). The 
lack of proliferation was not due to apoptosis as confirmed by 
annexin-V and 7-AAD staining (Figure 4B).
To investigate if MPLA-tDCs are able to induce phenotypic 
alterations in naive CD4+ T cells or imprint regulatory features, 
the expression of IL-10 and regulatory T cell markers was 
evaluated. Surprisingly, the percentage of Foxp3+ CD25hi cells 
was significantly lower when naive CD4+ T cells were primed 
by MPLA-tDCs or tDCs, compared to when iDCs or mDCs 
were used as stimulators (Figure 4A). Likewise, the expression 
of the co-inhibitory receptor CTLA-4 and the ectonucleotidase 
CD39, both involved in regulatory functions, was also reduced 
in CD4+ T cells primed by MPLA-tDCs or tDCs as compared to 
iDCs- or mDCs-primed CD4+ T cells (Figure 4A). There were 
also no significant differences regarding the expression of IL-10 
between CD4+ T cells primed by MPLA-tDCs, tDCs, iDCs, or 
mDCs (Figure 4A).
MPla-tDcs render naive and Memory 
cD4+ T cells hyporesponsive to 
restimulation
To evaluate if the first encounter with MPLA-tDCs affects CD4+ 
T cell function, we recovered CD4+ T lymphocytes from co-
cultures with different DC subtypes and re-challenged them with 
autologous unpulsed or PPD-pulsed mDCs. A reduced prolifera-
tive response and proinflammatory cytokines production were 
evidenced when recovered CD4+ T cells were co-cultured with 
unpulsed mDCs in comparison to pulsed conditions (data not 
shown). Memory CD4+ T cells recovered from co-cultures with 
tDCs and MPLA-tDCs exhibited a reduced proliferation and 
IFN-γ production in response to restimulation with PPD-pulsed 
mDCs, compared to memory CD4+ T cells derived from co-
cultures with iDCs or mDCs (Figures 3A–C). However, previous 
contact to MPLA-tDCs or tDCs also diminished IL-10 secretion 
by memory CD4+ T cells compared to those previously stimulated 
by mDCs (Figure 3D). No significant differences were evident in 
the IL-17 expression by memory CD4+ T cells primed by different 
DC subtypes (data not shown).
Naive CD4+ T cells that were initially co-cultured with tDCs or 
MPLA-tDCs exhibited lower proliferation and IFN-γ production 
toward restimulation with PPD-pulsed mDCs than those that 
were previously primed by PPD-loaded mDCs (Figures 4C–E). 
The response of tDCs-primed naive CD4+ T cells was also sig-
nificantly lower than that of iDCs-primed naive CD4+ T cells 
(Figures 4D,E). In contrast, IL-10 secretion levels did not differ 
between CD4+ T cells that were previously primed by iDCs, 
mDCs, tDCs, or MPLA-tDCs (Figure  4F). No significant dif-
ferences were evident in the IL-17 expression by memory CD4+ 
T cells primed by different DC subtypes (data not shown).
MPla-tDcs endow naive cD4+ T cells 
with the ability to suppress Th1 and  
Th17 responses
Having shown that MPLA-tDCs render naive CD4+ T cells hypore-
sponsive to second stimulation by mDCs, we wanted to investigate 
whether MPLA-tDCs also confer the ability to suppress effector T 
cell responses. Therefore, we co-cultured naive CD4+ T cells, previ-
ously primed by PPD-pulsed DCs, with autologous CFSE-labeled 
responder CD4+ T cells and PPD-pulsed mDCs (Figure  5A). 
FigUre 2 | MPla-tDcs modulate memory cD4+ T cells responses in an antigen-specific way. For the assessment of their T cell-stimulatory capacity, 
PPD-pulsed DCs were co-cultured with autologous CFSE-labeled memory CD4+ T cells. Un-loaded DCs were used as control. Data were normalized by subtracting 
values of unpulsed conditions to antigen-specific conditions. (a) Representative dot plots of IFN-γ (top) and IL-17 (bottom) expression from 10 independent 
experiments are shown. (B) Proliferation of CD4+ T cells was determined by CFSE dilution through flow cytometry, and graphic representation of normalized data of 
the percentage of CFSElow in CD4+ T cells is shown. (c) IFN-γ and (D) IL-17 expression was detected intracellularly and analyzed by flow cytometry. Graphic 
representation of normalized data of the percentage of IFN-γ and IL-17 producing proliferating CD4+ T cells (CFSElow) is shown. In (B–D), statistical differences were 
calculated using Friedman test followed by Duns post-test (*P < 0.05; ***P < 0.001). (e) Representative dot plots of cell viability measured after 6 days of co-culture 
and expressed as the percentage of annexin-V and 7-AAD-negative cells are shown.
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FigUre 3 | MPla-tDcs render memory cD4+ T cells to be hyporesponsive to restimulation. For restimulation assays, memory CD4+ T cells were primed 
with PPD-loaded DC subsets and then were recovered, washed, labeled with CFSE, and restimulated with unpulsed or PPD-pulsed mDCs. Data were normalized 
by subtracting values of unpulsed conditions to antigen-specific conditions. (a) Representative dot plots of IFN-γ expression from six independent experiments are 
shown. (B) Proliferation of restimulated primed-CD4+ T cells was determined by CFSE dilution through flow cytometry and graphic representation of normalized data 
of the percentage of CFSElow in CD4+ T cells is shown. (c) IFN-γ expression was detected intracellularly and analyzed by flow cytometry. Graphic representation of 
normalized data of the percentage of IFN-γ producing proliferating CD4+ T cells (CFSElow) is shown. (D) IL-10 secretion levels from mDC/primed-T cell co-culture 
supernatants were measured using ELISA. For (B–D), statistical differences were calculated using Friedman test (for non-parametric data) or one-way ANOVA (for 
normally distributed data) followed by Duns or Tukey post-test, respectively (*P < 0.05; **P < 0.01; ***P < 0.001).
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The  addition of previously primed naive CD4+ T cells to co-
cultures did not affect responder cell proliferation (Figure  5C). 
However, IFN-γ and IL-17 production by responder CD4+ T cells 
was markedly reduced in the presence of naive CD4+ T cells that 
were previously primed by MPLA-tDCs or tDCs in comparison 
to co-cultures that received mDC-primed naive CD4+ T cells and 
co-cultures performed in absence of primed-naive CD4+ T cells 
(Figures 5B,D,E), indicating that MPLA-tDCs confer suppressive 
features to these cells.
DiscUssiOn
Cell therapy based on tolerogenic DCs (tDCs) has become a 
promising alternative for the treatment of T cell-mediated auto-
immune pathologies (31). Our group has recently developed a 
shortened 5-day protocol for generation of alternatively activated 
tDCs, using Dex for modulation and MPLA as activating stimulus 
(26). The present study confirms the ability of these MPLA-tDCs 
to act at different levels of an immune response, preventing 
proinflammatory naive and memory CD4+ T cell responses. 
Moreover, MPLA-tDCs do not only render naive and memory 
T cells hyporesponsive to further stimulation by DCs but also 
imprint regulatory functions such as the suppression of Th1 and 
Th17 effector responses.
Consistent with our previous work, we observed low expres-
sion levels of costimulatory molecules, such as CD86, CD80, and 
CD83, in both tDCs and MPLA-tDCs, indicating that MPLA 
treatment does not affect the induction of a tolerogenic pheno-
type (26). Costimulatory ligands provide the “second signal” for 
T cell activation (32, 33), and their reduced expression on DCs is 
associated with a decreased capacity to initiate T cell responses 
and the promotion of tolerance through induction of T cell 
anergy and/or differentiation into Tregs (8).
As antigen capture is crucial to the presentation of exogenous 
antigen by DCs, we evaluated the effect of Dex and MPLA treat-
ment on the uptake of DX-FITC particles, which are mainly 
ingested via receptor-mediated endocytosis through mannose 
receptor (34). DCs that did not receive MPLA treatment (iDCs 
and tDCs) presented higher uptake of DX-FITC than MPLA-
treated DCs (mDCs and MPLA-tDCs). In accordance with the 
previous reports, Dex treatment of DCs even enhanced the 
rate of mannose receptor-mediated endocytosis as compared 
FigUre 4 | naive cD4+ T cells primed by MPla-tDcs do not exhibit a regulatory phenotype and become hyporesponsive to restimulation.  
MPLA-tDCs ability to induce phenotypic regulatory properties on naive CD4+ T cells after co-culturing was evaluated. (a) Expression of IL-10, FOXP3 in combination 
to CD25, CTLA-4, and CD39 was evaluated by flow cytometry. Graphic analyses of MFI measurements are expressed as box-and-whiskers plot from minimum to 
maximum values (n = 5). Statistical differences were calculated using Friedman test (for non-parametric data) or one-way ANOVA (for normally distributed data) 
followed by Duns or Tukey post-test, respectively (*P < 0.05; **P < 0.01; ***P < 0.001). (B) Representative dot plots of cell viability measured after 6 days of 
co-culture and expressed as the percentage of annexin-V and 7-AAD-negative cells are shown. For restimulation assays, naive CD4+ T cells were primed with 
PPD-loaded DC subsets and then were recovered, washed, labeled with CFSE, and restimulated with unpulsed or PPD-pulsed mDCs. Data were normalized by 
subtracting values of unpulsed conditions to antigen-specific conditions. (c) Representative dot plots of IFN-γ expression from six independent experiments are 
shown. (D) Proliferation of restimulated primed-CD4+ T cells was determined by CFSE dilution through flow cytometry, and graphic representation of normalized 
data of the percentage of CFSElow in CD4+ T cells is shown. (e) IFN-γ expression was detected intracellularly and analyzed by flow cytometry. Graphic representation 
of normalized data of the percentage of IFN-γ producing proliferating CD4+ T cells (CFSElow) is shown. (F) IL-10 secretion levels from mDC/primed-T cell co-culture 
supernatants were measured using ELISA. For (D–F), statistical differences were calculated using one-way ANOVA followed by Tukey post-test (*P < 0.05; 
**P < 0.01; ***P < 0.001).
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FigUre 5 | MPla-tDcs endow naive cD4+ T cells with the ability to suppress Th1 and Th17 responses. To evaluate the ability of MPLA-tDCs to induce 
functional regulatory properties on naive CD4+ T cells, these cells were primed with PPD-loaded DC subsets and then were recovered, washed, and added to a 
co-culture of CFSE-labeled responder CD4+ T cells and PPD-pulsed mDCs. Responder CD4+ T cells co-cultured with mDCs and without the addition of primed-
naive CD4+ T cells were used as control. (a) Gate strategy is shown: R1 = lymphocytes region, R2 = CFSE + population. (B) Representative dot plots of IFN-γ (top) 
and IL-17 (bottom) expression from seven independent experiments are shown. (c) Proliferation of responder CD4+ T cells in presence of primed-naive CD4+ T cells 
was determined by CFSE dilution through flow cytometry, and graphic representation of the percentage of CFSElow in CD4+ T cells is shown. (D) IFN-γ and (e) IL-17 
expression were detected intracellularly and analyzed by flow cytometry. Graphic representation of the percentage of IFN-γ and IL-17 producing proliferating CD4+ 
T cells (CFSElow) is shown. For (c–e), statistical differences were calculated using one-way ANOVA followed by Tukey post-test (*P < 0.05; **P < 0.01).
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to iDCs (35). As antigen uptake is a hallmark of immature DCs 
and decreases upon maturation (34), antigen loading has to be 
accomplished prior to application of maturation stimuli such as 
MPLA. Therefore, in our experimental model, mDCs and MPLA-
tDCs were exposed to PPD antigen 4 h before addition of MPLA, 
enabling sufficient antigen uptake.
It has been reported that activation of tDCs by adding TLR 
ligands or proinflammatory cytokines increases the antigen-
presenting capacity, which is indispensable for antigen-specific 
therapeutic approaches (28). Applying MPLA as activation 
stimulus, we achieved HLA-DR levels on MPLA-tDCs similar to 
their mature counterparts, suggesting that MPLA-tDCs are able to 
present antigen. Using an hCII-specific murine T cell hybridoma 
derived from HLA-DR1 transgenic mice (36), we confirmed that 
MPLA-tDCs are able to present antigens efficiently, similar to 
mDCs and more efficient than tDCs.
The hitherto described tolerogenic features of MPLA-tDCs, in 
addition to the previously reported (26), make them a promising 
candidate for immunotherapy of autoimmune diseases. However, 
more sophisticated in  vitro and in  vivo studies are required to 
validate their suitability for the transfer to clinical application. To 
attend this requirement, we evaluated the ability of MPLA-tDCs 
to modulate antigen-specific naive and memory CD4+ T  cell 
responses using PPD as model antigen. MPLA-tDCs were poor 
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inducers of proliferation and IFN-γ and IL-17 production in 
PPD-specific memory CD4+ T cells. This effect was not associated 
with an induction of apoptosis, suggesting rather reprograming 
than deletion of antigen-specific memory CD4+ T cells (27). We 
confirmed this hypothesis of “reprograming” by a restimulation 
assay, subjecting memory CD4+ T cells, recovered from co-
cultures with different DC subtypes, to a second stimulation with 
PPD-pulsed mDCs. Only memory CD4+ T cells that had previ-
ously contact to mDCs or iDCs proliferated and produced IFN-γ 
in response to the second stimulus, while memory CD4+ T cells 
derived from co-cultures with MPLA-tDCs or tDCs remained 
completely unresponsive to antigen-specific stimulation.
Interestingly, naive CD4+ T cells did not proliferate after first 
encounter with different DC subsets. It is conceivable that naive 
CD4+ T cells received an initial “imprinting” by the respective 
DC subset but need a prolonged time of stimulation or a second 
encounter with DCs to develop a proliferative response. However, 
an “imprinting” of naive CD4+ T cells by tDCs and MPLA-tDCs 
confers hyporesponsiveness in terms of proliferation and IFN-γ 
production toward second stimulation with PPD-pulsed mDCs.
Unlike other studies, in which priming with Dex-treated DCs 
increases the number of IL-10-producing cells both in vivo and 
in vitro (37, 38), in our model, there were no significant differ-
ences in IL-10 expression between naive CD4+ T cells primed 
with different DC subsets. This could be due to the fact that 
repetitive rounds of priming with tDCs are necessary to modulate 
T cells properties, as reported by Unger and colleagues (39). This 
would explain why we were not able to observe a typical Treg 
phenotype on naive CD4+ T cells primed by MPLA-tDCs or 
tDCs. It has to be considered that the analyzed markers are not 
exclusively expressed by Tregs but also by activated T cells (31). 
Thus, it is essential to unravel markers that specifically define and 
distinguish distinct T cell populations with regulatory properties.
The observed “reprograming” of antigen-specific naive and 
memory CD4+ T cells by MPLA-tDCs to a stable hyproresponsive 
state is in accordance with a study of Woltman and colleagues 
(29) and suggests that in the context of autoimmunity, transferred 
autologous MPLA-tDCs would be able to silence autoreactive T 
cell responses, either at their initiation, preventing the differentia-
tion of autoantigen-specific naive CD4+ T cells toward proinflam-
matory Th1 or Th17 cells, or by turning off already developed 
effector T cell responses.
Anergy induction appears to be a promising strategy to 
specifically target pathologic T cell responses without generat-
ing undesired side effects. Several studies have demonstrated 
that the induction of CD4+ T cell anergy efficiently controls 
responses against disease-associated autoantigens in patients with 
autoimmune pathologies in vitro (24, 40, 41), preventing disease 
progression in vivo (14, 42). Furthermore, it has been reported 
that hyporesponsive CD4+ T cells can also acquire suppressive 
capacities, supporting their role in the restoration of tolerance 
(43, 44).
Likewise, an important finding of this work is that despite the 
lack of characteristic Treg markers, naive CD4+ T cells primed in 
tolerogenic conditions, i.e., the presence of MPLA-tDCs or tDCs, 
acquired immunomodulatory functions, inhibiting the polariza-
tion of responder CD4+ T cells to Th1 and Th17 profiles. There 
are three possible mechanisms: first, we are generating hypore-
sponsive CD4+ T cells with suppressive capacities, as described 
previously (43, 44). Second, naive CD4+ T cells primed by MPLA-
tDCs or tDCs might compete with effector CD4+ T cells for the 
contact to mDCs, thereby preventing the development of an 
immunological synapse and an efficient T cell activation. Third, 
MPLA-tDC- or tDC-primed naive CD4+ T cells might express 
yet unknown mediators that either inhibit DC function (45) or 
render effector T cells anergic (46).
In this work, we investigated different scenarios that 
antigen-loaded MPLA-tDCs might encounter in vivo, e.g., when 
transferred into a patient with autoimmune disease, including 
naive autoantigen-specific CD4+ T cells and mDCs in the lymph 
node, or autoreactive memory CD4+ T cells and inflammatory 
DCs in inflamed tissues. We showed that MPLA-tDCs were able 
to reprogram memory CD4+ T cells to become anergic toward 
second stimulation and to imprint regulatory functions on naive 
CD4+ T cells. Although further in vivo studies are required, our 
results provide important evidence that MPLA-tDCs are suitable 
immunotherapeutics for the establishment of antigen-specific 
tolerance in autoimmunity and transplantation.
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